Daridorexant for People With Insomnia and Alcohol Use Disorder Study
NCT: NCT07701928 · NOT_YET_RECRUITING
Brief Summary
The goal of this clinical trial is to see if a sleep medication, daridorexant (DTX), can help decrease drinking in people who have alcohol use disorder (AUD) and insomnia. The main questions it aims to answer are: * Can DTX decrease alcohol use in individuals with insomnia better than placebo? * Can DTX increase sleep time and other sleep related outcomes better than placebo? Participants will: * Take prescribed medication (DTX or Placebo based on which group they are randomized to). * Provide urine, breath, saliva, and blood samples. * Come in for bi-weekly (once every 2 weeks) in-person visits. * Answer questionnaires and surveys related to sleep, substance use, and physical/mental health. * Use an EEG headband to track brain activity at night. * Come in for 3 follow up visits one month, six months, and one year after treatment.
Frequently Asked Questions
What is Daridorexant for People With Insomnia and Alcohol Use Disorder Study?
Daridorexant for People With Insomnia and Alcohol Use Disorder Study is a clinical trial registered under NCT07701928. Current status: NOT_YET_RECRUITING.
What is the status of NCT07701928?
The current status of NCT07701928 (Daridorexant for People With Insomnia and Alcohol Use Disorder Study) is: NOT_YET_RECRUITING.
When did Daridorexant for People With Insomnia and Alcohol Use Disorder Study start?
Daridorexant for People With Insomnia and Alcohol Use Disorder Study started on 2026-09-01.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.